November 1, 2012
At the 8th Annual Meeting of the Oligonucleotide Therapeutics Society, held in Boston October 28-31, 2012, we presented exciting data covering several of the company’s therapeutic programs and delivery platforms.
THERAPEUTIC PROGRAMS
Therapeutic research highlighted recent clinical and pre-clinical work from our programs in transthyretin-mediated amyloidosis (TTR), hemophilia, hypercholesterolemia, and liver cancer. Click here for presentations.
October 3, 2012
Alnylam scientists and collaborators today published a paper in Cell Metabolism demonstrating that lowering levels of a liver gene called XBP1 through RNAi or genetic ablation reduced plasma lipid levels and improved hepatic steatosis, liver damage, and hypercholesterolemia in mice. The changes in lipid parameters were shown to result from activation of IRE1α and a process known as regulated IRE1-dependent decay (RIDD), whereby certain cytosolic mRNAs are degraded…
October 3, 2012
June 22, 2012
March 27, 2012
March 1, 2012
Our scientists presented an update on our RNAi delivery strategies at the AsiaTIDES conference this week. The presentation focuses on our recent progress utilizing conjugates and lipid nanoparticles for systemic adminstration of RNAi therapeutics.
View our presentation (2.4MB PDF)February 9, 2012
Our scientists discovered a new method for monitoring RNAi activity in blood samples. The results were presented at the Keystone Gene Silencing by small RNAs symposium (Vancouver, February 7-12). This new method, circulating extracellular RNA detection (cERD), allows quantitative measurement of tissue-specific mRNA silencing from biological fluids including blood and cerebrospinal fluid (CSF).
View our poster (1.18 MB PDF) Read our press release
